Product image of Mimpara (Cinacalcet) supplied by GNH India

Mimpara

Active Ingredient:
Cinacalcet
Origin:
EU

Mimpara (Cinacalcet)

Cinacalcet, the active ingredient in Mimpara, is a calcimimetic presented as a 30 mg tablet (also available as 60 mg tablet) for oral use. It treats secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and primary hyperparathyroidism when parathyroidectomy is not indicated.

GNH India supplies Mimpara as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide, providing reliable sourcing for clinical and research use.

Manufacturer / TM Owner

Amgen Europe B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mimpara (cinacalcet) is used to manage disorders of calcium metabolism related to parathyroid hormone dysregulation.

  • Secondary hyperparathyroidism (CKD on dialysis): reduces elevated parathyroid hormone levels and helps control serum calcium and phosphorus.
  • Primary hyperparathyroidism (non‑surgical candidates): lowers PTH secretion when parathyroidectomy is not indicated.

How It Works

  • Cinacalcet acts as an allosteric activator of the calcium‑sensing receptor on parathyroid cells. By increasing the receptor’s sensitivity to extracellular calcium, it suppresses parathyroid hormone (PTH) secretion, leading to reduced serum calcium and phosphorus concentrations in patients with hyperparathyroidism.

Side Effects

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Vomiting: occasional episodes, often transient.
  • Diarrhea: loose stools, usually self‑limiting.
  • Hypocalcemia: low serum calcium levels, may cause tingling.
  • Muscle cramps: intermittent discomfort.
  • Headache: mild to moderate intensity.

Serious or Rare Side Effects

  • Severe hypocalcemia: can lead to seizures or cardiac arrhythmias.
  • Cardiac arrhythmias: irregular heart rhythms requiring monitoring.
  • Seizures: rare neurologic events.
  • Pancreatitis: inflammation of the pancreas, presenting with abdominal pain.
  • Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.

Precautions & Warnings

Before initiating therapy, consider the following precautions:

  • Monitor serum calcium: regular testing to avoid hypocalcemia.
  • Adjust dose in renal impairment: reduced clearance may require lower doses.
  • Cardiac caution: use carefully in patients with known arrhythmias.
  • Hypersensitivity: discontinue if allergic reactions occur.
  • Review concomitant calcium‑affecting drugs: assess risk of additive effects.
  • Store at below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Cinacalcet may interact with several medicines; awareness of the interaction level is essential.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase cinacalcet plasma concentrations.
  • Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect.
  • High‑dose calcium supplements: can blunt the drug’s calcium‑lowering action.

Moderate Interactions (Monitor Closely)

  • Vitamin D analogs (e.g., calcitriol): combined use may heighten hypocalcemia risk.
  • Loop diuretics: may affect calcium balance, requiring closer monitoring.
  • Warfarin: may necessitate INR checks due to potential interaction.

Frequently Asked Questions

Mimpara is indicated for secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis, and for primary hyperparathyroidism in individuals for whom parathyroidectomy is not appropriate or feasible.

Cinacalcet binds to the calcium‑sensing receptor on parathyroid cells and increases its sensitivity to extracellular calcium. This enhanced sensing reduces the secretion of parathyroid hormone, thereby lowering serum calcium and phosphorus concentrations.

The specific dose of Mimpara is determined by the prescribing clinician based on the patient’s laboratory values, renal function, and therapeutic response. Dosage adjustments are made to achieve target calcium and PTH levels.

The safety of cinacalcet in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Mimpara, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mimpara belongs to the calcimimetic class, which directly targets the calcium‑sensing receptor, unlike vitamin D analogs or phosphate binders that act indirectly. It offers an oral option for patients unsuitable for surgery, providing a distinct mechanism of action compared with surgical or other pharmacologic approaches.

Mimpara tablets should be stored at temperatures below 25 °C, kept in the original packaging to protect from moisture, and placed out of direct sunlight. Do not freeze the tablets.

Mimpara is taken orally, usually once daily, with or without food, as directed by the prescribing physician. The tablet should be swallowed whole with a glass of water and not chewed or crushed.

The most serious risks include severe hypocalcemia, which can lead to seizures or cardiac arrhythmias, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for signs of low calcium and any unusual skin changes.

Mimpara should be avoided in individuals with known hypersensitivity to cinacalcet or any tablet excipients, and in patients with uncontrolled severe hypocalcemia. Caution is also advised for those with significant cardiac arrhythmias until calcium levels are stabilized.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Cinacalcet

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT